Today we posted on ASH 2018: Dr. Lindsey Roeker research from ASH 2018 on real world use of venetoclax for CLL: Turns out venetoclax works as well in the community as not does in trial: For more see: cllsociety.org/2019/06/ash-... Stay strong. We are all in this together. Brian
ASH 2018: Dr. Lindsey Roeker research from ASH... - CLL Support
Thanks Brian. It's particularly encouraging to know that Venetoclax is equally effective outside of the additional oversight of clinical trials, though Tumour Lysis Syndrome obviously still needs to be carefully managed.
Good to see the CLL Society is working to financially encourage new minds into CLL research. I hope you are able to adequately fund promising candidates through donations.
Second Neil’s points. Deeply encouraging and reassuring feedback (from someone who has recently started Venetoclax).
Jackie posted this about Venetoclax today.
My question, they feel that non-adherence may be one reason to blame for this mutation. Could a lower dose of Venetoclax also cause this? I know lower doses of ibrutinib are used but generally discouraged when possible.
Not sure there is any data on this being the cause.